enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
0.9041
+0.0106 (1.19%)
At close: Aug 27, 2025, 4:00 PM
0.9195
+0.0154 (1.70%)
After-hours: Aug 27, 2025, 7:58 PM EDT
enVVeno Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
17.40M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NVNO News
- 7 days ago - enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) - Accesswire
- 12 days ago - enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Accesswire
- 21 days ago - Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency - Accesswire
- 23 days ago - enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company - Accesswire
- 26 days ago - enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 5 weeks ago - enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - Accesswire
- 2 months ago - Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Accesswire
- 3 months ago - enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Accesswire